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Active pharmaceutical ingredients (APIs) are most con-
veniently developed and delivered orally as solid dosage
forms that contain a defined crystalline form of an API.
Co-crystal is a crystalline entity formed by two different
or more molecular entities where the intermolecular
interactions are weak forces like hydrogen bonding and
π-π stacking. Co-crystals are an enabling technology that
is used in new or existing drug delivery systems by
majority of pharmaceutical companies in formulation
and drug development. The concept of modifying the
properties of a drug molecule by forming a pharmaceut-
ical co-crystal containing a single APIs and a pharma-
ceutical relevant co-former with improved properties
compared with the pure drug crystal has generated
immense interest [1]. Physicians prescribe combination
therapy frequently to treat and manage a plethora of
medical conditions. Multi-API co-crystals, relatively
unexplored solid forms of APIs, have potential relevance
in the context of combination drugs for pharmaceutical
drug development (Figure 1).
The idea of developing multi-API co-crystals is inter-
esting. This is reflected from the number of publications
and patent applications for co-crystals in recent years.
Drug-drug co-crystals fulfil the criteria for patent eligi-
bility: novelty, utility, and non-obviousness for pharma-
ceutical development. However, no compilation of drug-
drug co-crystals information’s is available in literature.
There is immense potential to explore co-crystal design
of established APIs among each other to enhance solu-
bility and bioavailability of the product. Consequently,
there is a strong need to devise ways to increase the like-
lihood of success in generating drug–drug co-crystals. In
this context, the limited available reports in literature
are described here. While co-administering a combin-
ation of theophylline and phenobarbital, it was discov-
ered that a co-crystal of 2:1 stoichiometry existed
between the two compounds [2]. The example of a tri-
morphic co-crystal involving APIs i.e. ethenzamide and
gentisic acid, may find relevance in the context of
combination drugs [3]. The meloxicam-aspirin co-crystal
decreased the time required to reach the human thera-
peutic concentration compared with the parent drug,
meloxicam [4]. Higher degree of solubility of acetyl-
salicylic acid: (L)-theanine [(L)-5-N-ethyl-glutamine]
co-crystal system enables aspirin formulations for intra-
venous administration [5]. The 1:1 acetaminophen/
theophylline (AT) co-crystal had a faster dissolution rate
than AT physical mixtures [6]. Pharmaceutical compos-
ition comprising therapeutically effective amount of lami-
vudine: zidovudine co-crystals use for manufacture of
medicament for treatment of HIV infections of humans
was reported [7]. A single step co-deposition of albuterol
sulphate: ipratropium bromide co-crystal aerosols was
reported [8]. Two 1:1 drug-drug co-crystals [isoniazid: 4-
aminosalicylic acid; pyrazinamide: 4-aminosalicylic acid]
may be exploited for the treatment of tuberculosis [9].
Celecoxib: venlafaxine co-crystal and tramadol: celecoxib
co-crystals use as medicaments, more particularly for the
treatment of pain has been reported [10]. Amoxicillin-
clavulanate co-crystal improved its antibiotic activity
against non-beta lactamase bacterial, Sarcina lutea [11].
Further, many pharmaceutical companies and various
groups are working actively on co-crystals. Success
has been achieved for various co-crystal systems such
as sulfamethazine-theophylline, pyrazinamide-diflunisal,
sulfamethazine-potassium salt of 4-aminobenzoic acid,
theophylline: gentisic acid, ethenzamide-gentisic acid,
succinic acid (SA)-pyrazinamide (PZA)–isoniazid (INH)
two-drug combination composed of the co-crystals
PZA–(SA)0.5 and INH– SA(0.5).
In view of the reported generation of pharmaceutical
co-crystals containing two active pharmaceutical ingredi-
ents mentioned above, drugs having similar structure
and similar 3-D arrangement should be exploited for
drug-drug synergism to obtain multiple API co-crystals.
Co-crystal screening technology has the potential
to identify and establish new IP for new drug-drug co-
crystals of multiple APIs to protect the product from
competition. Further, it offers immense potential in
various fields such as resolution of racemic drugs to
enantiomerically pure isomers by single pure enantioner Correspondence: sekhon224@yahoo.com
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tion of co-crystal screening may lead to commerciali-
zation of new co-crystal product along with separated
single enantiomers. In the case of commercial API-API
combination, a patent of a drug-drug co-crystal with bet-
ter drug properties than previously known forms could
be of high commercial value. Designing drug-drug co-
crystals of marketed drugs may shorten development
period (including clinical trials) than those of New
Chemical Entities as co-crystals do not involve structural
modification of the APIs.
Co-crystals are less prone to suffer polymorphic trans-
formations and the status of polymorphism in this class
of co-crystals needs investigation. Co-crystals among APIs
such as aspirin, caffeine, theophylline, sulphadimidine,
carbamazepine, fluoxetine hydrochloride, piroxicam, nor-
floxacin, indomethacin, ibuprofen, paracetamol, flurbipro-
fen, itraconazole are of interest for multi-API co-crystals
study. A single-step, scalable, solvent-free, continuous co-
crystallization and agglomeration technology developed
for co-crystal agglomerates of ibuprofen: nicotinamide
(1:1 ratio) using Hot Melt Extrusion, offer the flexibility
for tailoring the co-crystal purity. The potential of super-
critical fluids as new media for the co-crystallization of
APIs has been addressed recently and screening for
pharmaceutical co-crystals using the supercritical fluid
enhanced atomization process might help for production
of multi-API co-crystals. Experts are of the opinion that
multi-API co-crystals are expected to overcome the pro-
blems associated with traditional combination drugs and
it is hoped that further research in this area may have
some bearing in the treatment of several diseases.
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Figure 1 Representation of drug-drug co-crystal and
combination drug.
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